triazolam has been researched along with Temporomandibular Disorders in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with chronic orofacial pain often report disturbances in sleep, leading to the hypothesis that nocturnal motor hyperactivity of the muscles of mastication may contribute to the nociceptive process." | 2.69 | Triazolam improves sleep but fails to alter pain in TMD patients. ( DeNucci, DJ; Dionne, RA; Sobiski, C, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeNucci, DJ | 1 |
| Sobiski, C | 1 |
| Dionne, RA | 1 |
1 trial available for triazolam and Temporomandibular Disorders
| Article | Year |
|---|---|
Triazolam improves sleep but fails to alter pain in TMD patients.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Electromyography; Facial Pain; GABA | 1998 |